Imprint
Privacy Policy

“Glioblastoma is one of the most complex, deadly, and treatment-resistant cancers.”
– National Brain Tumor Society

We are developing personalised therapy for Glioblastoma by eliminating its root cause – Glioma Initiating Cells.

The Problem

Glioblastoma (GB) is one of the most aggressive brain tumors, affecting around 300,000 people worldwide each year. Despite advancements in treatment, the prognosis remains challenging. Standard treatments, including a combination of chemotherapy and radiation, have improved survival rates, but the average life expectancy remains around 14.6 months. For recurrent GB, treatments like Avastin® (bevacizumab) offer some benefit, while Optune® (Tumor Treating Fields) provides a non-invasive option to slow tumor growth.

The Root Cause

A small fraction of cancer cells (<5%), known as glioblastoma-initiating cells (GICs) or cancer stem cells (CSCs), is the root cause of tumor recurrence. These cells drive tumor growth and resist standard treatments like chemotherapy and radiation, allowing the cancer to return even after aggressive therapy. Developing effective treatments targeting GICs/CSCs to preventing recurrence and improving patient outcomes.

Our Approach

At GliTTher, we are developing a treatment designed to complement standard glioblastoma care. During surgery, we perform a diagnostic test to identify patients who are most likely to benefit. The surgeon then applies our therapy locally and installs a catheter for targeted reapplication over 10 days, optimising effectiveness. This approach integrates with existing treatments to enhance outcomes and help reduce recurrence.

Our Assets

Screening Platform

We have a proprietary drug screening platform which allows us specifically identify candidates that can target GICs.

Lead Compounds

Our pipeline includes five lead compounds that have been in vivo validated to selectively eliminate GICs.

Biomarker Candidates

Our biomarker candidates enable patient stratification, helping identify those most likely to benefit from our therapy.

Team

Dr. Sammy Mahdi
Chief Executive Officer
Co-Founder

Dr. Virginie Clement-Schatlo
Chief Scientific Officer
Co-Founder

Alexander Berg
Strategic Advisor
Co-Founder

For more information and inquires please contact us at i n f о [аt] g l i t t h e r . c о m

All rights reserved. Designed with WordPress. Icons: Flaticon.com